Sandoz to offer generic Solaraze
Sandoz has announced the U.S. launch of an authorized generic version of PharmaDerm’s Solaraze Gel (diclofenac 3% gel), which generated $92 million in 2012.
Sandoz has announced the U.S. launch of an authorized generic version of PharmaDerm’s Solaraze Gel (diclofenac 3% gel), which generated $92 million in 2012.
Diclofenac 3% gel is an approved topical treatment of actinic keratosis, a precancerous condition of thick, scaly, or crusty patches of skin that affects an estimated 58 million Americans. Sandoz will market its diclofenac gel in the 3% strength.
“As the global leader across a broad range of differentiated generic categories, Sandoz is pleased to offer a high-quality generic version of this important medicine to U.S. patients,” said Peter Goldschmidt, president of Sandoz US. “This important launch further strengthens our U.S. and global leadership in topical generic dermatology.”
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
